Jefferies Assumes Spectrum Pharmaceuticals (SPPI) at Buy

February 10, 2017 6:44 AM UTC Send to a Friend
Jefferies initiates coverage on Spectrum Pharmaceuticals (NASDAQ: SPPI) with a Buy rating and a price target of $7.50.Analyst Matthew Andrews ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login